To recover your password please fill in your email address
Please fill in below form to create an account with us
MOST 18 SUBSTUDY 40: DURVALUMAB PLUS CHEMOTHERAPY
A single-arm, open-label, signal-seeking, phase II trial of durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma
|
Trial Summary: |
The aim of this MoST substudy is to assess the clinical activity of first line durvalumab and chemotherapy in patients with extensive stage- extrapulmonary small cell carcinomas |
|
Supported By: |
AGCMC, AstraZeneca |
|
Eligibility: |
Adults with treatment naïve extensive stage- extrapulmonary small cell carcinomas enrolled on the MoST program are eligible for this study |
|
Registration ID: |
ACTRN12621001225808 |
|
Participation: |
National |
|
Status: |
In follow-up |
|
Activation Date: |
16/03/2022 |
|
Chair: |
Dr Peey-Sei Kok |
|
Contact: |